Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Acta Cir Bras ; 38: e385623, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38055383

RESUMO

PURPOSE: Diabetes mellitus is a serious health problem worldwide, and diabetic nephropathy is the complication. The diabetic nephropathy considerably enhances the oxidative stress, glycation, lipid parameters and inflammatory reaction. Ellipticine has potent free radical scavenging and anti-inflammatory effect. METHODS: In the current study, our objectives were to thoroughly examine the renal protective effects of ellipticine in a rat model of streptozotocin (STZ)-induced diabetic nephropathy (DN) and to elucidate the underlying mechanisms involved. For the induction of diabetic nephropathy, streptozotocin (50 mg/kg) was used, and rats were separated into groups and given varying doses of ellipticine (2.5, 5 and 7.5 mg/kg). The body weight, and renal weight were estimated. The inflammatory cytokines, renal biomarkers, inflammatory antioxidant, and urine parameters were estimated. RESULTS: Result showed that ellipticine considerably enhanced the body weight and reduced the renal tissue weight. Ellipticine treatment significantly (P < 0.001) repressed the level of blood urea nitrogen, serum creatinine, uric acid, blood glucose and altered the lipid parameters. Ellipticine significantly (P < 0.001) repressed the level of malonaldehyde and boosted the glutathione, catalase, superoxide dismutase, and glutathione peroxidase. Ellipticine treatment significantly (P < 0.001) reduced the inflammatory cytokines and inflammatory mediators. CONCLUSIONS: Ellipticine could be a renal protective drug via attenuating the inflammatory reaction, fibrosis and oxidative stress in streptozotocin induced rats.


Assuntos
Diabetes Mellitus , Nefropatias Diabéticas , Elipticinas , Ratos , Animais , Nefropatias Diabéticas/tratamento farmacológico , Nefropatias Diabéticas/prevenção & controle , Nefropatias Diabéticas/metabolismo , Estreptozocina/metabolismo , Estreptozocina/farmacologia , Estreptozocina/uso terapêutico , Elipticinas/metabolismo , Elipticinas/farmacologia , Elipticinas/uso terapêutico , Rim , Estresse Oxidativo , Citocinas/metabolismo , Mediadores da Inflamação/metabolismo , Peso Corporal , Diabetes Mellitus/metabolismo
2.
Phytomedicine ; 20(1): 71-6, 2012 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-23092722

RESUMO

Indole alkaloids ellipticine (1), cryptolepine triflate (2a), rationally designed 11-(4-piperidinamino)cryptolepine hydrogen dichloride (2b) and olivacine (3) (an isomer of 1) were evaluated in vitro against Plasmodium falciparum and in vivo in Plasmodium berghei-infected mice. 1-3 inhibited P. falciparum (IC50≤1.4 µM, order of activity: 2b>1>2a>3). In vitro toxicity to murine macrophages was evaluated and revealed selectivity indices (SI) of 10-12 for 2a and SI>2.8×10² for 1, 2b and 3. 1 administered orally at 50mg/kg/day was highly active against P. berghei (in vivo inhibition compared to untreated control (IVI)=100%, mean survival time (MST)>40 days, comparable activity to chloroquine control). 1 administered orally and subcutaneously was active at 10 mg/kg/day (IVI=70-77%; MST=27-29 days). 3 exhibited high oral activity at ≥50 mg/kg/day (IVI=90-97%, MST=23-27 days). Cryptolepine (2a) administered orally and subcutaneously exhibited moderate activity at 50mg/kg/day (IVI=43-63%, MST=24-25 days). At 50 mg/kg/day, 2b administered subcutaneously was lethal to infected mice (MST=3 days) and moderately active when administered orally (IVI=45-55%, MST=25 days). 1 and 3 are promising compounds for development of antimalarials.


Assuntos
Antimaláricos/uso terapêutico , Aspidosperma/química , Elipticinas/uso terapêutico , Alcaloides Indólicos/uso terapêutico , Malária/tratamento farmacológico , Fitoterapia , Extratos Vegetais/uso terapêutico , Quinolinas/uso terapêutico , Animais , Antimaláricos/farmacologia , Elipticinas/isolamento & purificação , Elipticinas/farmacologia , Feminino , Alcaloides Indólicos/isolamento & purificação , Alcaloides Indólicos/farmacologia , Macrófagos/efeitos dos fármacos , Malária/parasitologia , Camundongos , Camundongos Endogâmicos , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Plasmodium berghei/efeitos dos fármacos , Plasmodium falciparum/efeitos dos fármacos , Quinolinas/isolamento & purificação , Quinolinas/farmacologia
3.
Ciênc. cult. (Säo Paulo) ; 49(5/6): 370-7, Sept.-Dec. 1997. tab, graf
Artigo em Inglês | LILACS | ID: lil-214099

RESUMO

Several derivatives of well-known natural anticancer drugs have been synthesized and will continue to be, to overcome their delivering problems, or effectiveness. Characteristics such as poor solubility, metabolic inactivation, resistance development, rapid clearance or short half-life, adverse side effects like nausea, alopecia, anorexia are common undesirable limitations to their clinical use. Drug toxicity to less sensitive tumors as those in liver or brain is another aimed goal. Recent efforts to reverse undesirable physicochemical properties of well-established natural anticancer compounds are focused. Improved antitumor action of olivacine in L(1210) leukemia with slightly soluble halides with increased life span as well as "cured" animals was observed.


Assuntos
Humanos , Antineoplásicos Fitogênicos/farmacologia , Elipticinas/farmacologia , Leucemia L1210/tratamento farmacológico , Antineoplásicos Fitogênicos/uso terapêutico , Elipticinas/uso terapêutico , Sobrevivência Celular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA